Lv52
960 积分 2022-04-17 加入
Oral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design
22小时前
待确认
Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue
5天前
已完结
Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers
5天前
已完结
Leveraging Structure-Based Design to Overcome Class III RTK Off-Target Activity in the Development of Selective Wild-Type KIT Inhibitors
8天前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
11天前
已完结
Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors
14天前
已完结
Structural basis for high-affinity inhibitor binding to lipid kinases PIP4K2A and PIP4K2B
18天前
已完结
Lead Optimization of Multimutant KRAS Switch-II Pocket Macrocyclic Inhibitors via Isosteric Replacement to Improve ADME and Oral Exposure
18天前
已完结
Sulfoximines as Secondary Sulfonamide Isosteres: Paradoxical Impact on Solubility and Plasma Protein Binding
18天前
已完结
Discovery ofHighly Potent and Selective, Orally BioavailableBTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads
27天前
已完结
皖公网安备34019202002308
